Seven months after Novo Nordisk abandoned its push into cell therapy, the pharma’s Parkinson’s disease program looks like ...

The University of Texas MD Anderson Cancer Center and CTMC, a joint venture between UT MD Anderson and Resilience, today ...

Sana Biotechnology (NASDAQ:SANA) is one of the small cap stocks with the highest upside potential. On April 13, Sana Biotechnology and Mayo Clinic entered into a collaboration to accelerate the ...

Stem cell therapy may offer relief for some people with early knee damage or mild osteoarthritis and could help delay surgery ...

Americans Skip Overseas Travel as Stem Cell Exosome Therapy Lands at 5 U.S. Locations New York, United States - May 14, ...

When the CEO of Nvidia talks, decision-makers listen, from investors to business executives to Nobel Prize committees. Ever since Jensen Huang observed six months ago that “for the first time in human ...

Data presented at AD/PD™ 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders Oryon Cell Therapies (“Oryon”),a clinical-stage biotechnology company ...

Shelved therapy revived: Cellular Intelligence takes over Novo Nordisk’s discontinued Parkinson’s treatment, STEM-PD, aiming to advance it through AI-powered development. Deal structure: Novo gains ...

ORLANDO, Fla — Stem cell–derived beta-cell replacement therapy continues to show benefit in people with type 1 diabetes at a high risk for severe hypoglycemia. Of a total 17 patients who received a ...

May 11 (Reuters) - Meta CEO Mark Zuckerberg backed-Cellular Intelligence has acquired Danish drugmaker Novo Nordisk's cell therapy candidate for Parkinson's disease, the biotech firm said on Monday.